In December 2023, Pfizer completed its $43 billion acquisition of Seagen, a biotech firm specializing in antibody-drug conjugates, significantly bolstering its oncology portfolio and aiming to double its cancer treatment pipeline. Earlier in May 2023, the FDA approved Pfizer's Abrysvo vaccine for respiratory syncytial virus (RSV), marking a key milestone in addressing a major cause of infant hospitalizations and positioning the company as a leader in preventive medicine for vulnerable populations. Throughout 2023 and into 2024, Pfizer advanced its mRNA technology platform, building on COVID-19 vaccine success, with ongoing trials for flu and shingles vaccines in collaboration with BioNTech. Additionally, in October 2024, Pfizer announced positive phase 3 results for its once-daily oral weight loss drug danuglipron, potentially entering the competitive obesity market dominated by injectables.

Pfizer, founded in 1849 and headquartered in New York City, is a global biopharmaceutical giant with over 83,000 employees, focusing on innovative medicines in areas like oncology, immunology, and rare diseases. The company generates around $58 billion in annual revenue, with a strong emphasis on research and development, investing about $10 billion yearly to fuel its pipeline of over 100 clinical programs. Currently, Pfizer is positioning itself as a post-pandemic powerhouse by diversifying beyond COVID-19 products, leveraging acquisitions and partnerships to expand in high-growth fields like gene therapy and precision medicine. Its strategic shift includes cost-cutting measures, such as a $3.5 billion savings plan announced in 2023, to improve efficiency amid declining vaccine sales. This positioning appeals to young professionals seeking roles in cutting-edge science and technology within a stable, large-scale organization.

Pfizer's tech division excels through its Digital and Technology organization, which integrates AI and machine learning for drug discovery, such as using predictive modeling to accelerate clinical trial designs and reduce development timelines. The company employs advanced software platforms like its proprietary Pfizer Digital tools for real-time data analytics in supply chain management and patient monitoring via wearable integrations. In the highly innovative biopharma industry, Pfizer is well-positioned with collaborations like its AI partnership with IBM Watson for immuno-oncology research, fostering rapid advancements in personalized medicine. Reputation-wise, Pfizer offers competitive salaries averaging $120,000-$150,000 for software engineers and product roles, with strong career development through rotational programs and mentorship, though some reviews note bureaucratic hurdles in innovation pace.

Pfizer faces weaknesses such as patent expirations on blockbuster drugs like Eliquis, projected to lose exclusivity by 2026, potentially eroding $7 billion in revenue amid generic competition. Opportunities abound in expanding its oncology franchise post-Seagen acquisition, targeting a market expected to reach $300 billion by 2026, and venturing into emerging therapies like CRISPR gene editing through partnerships. Threats include intense rivalry from peers like Merck and Moderna, who are advancing similar mRNA and cancer treatments, alongside regulatory scrutiny from agencies like the FDA that could delay approvals. Additionally, supply chain vulnerabilities, highlighted by global disruptions, pose risks to manufacturing, while pricing pressures from governments and insurers challenge profitability in key markets.